Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 15.0 | 89 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 17.0 | 96 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 22.0 | 84 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 16.0 | 96 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 20.5 | 78 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 19.0 | 79 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 23.0 | 84 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 44.0 | 63 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 47.0 | 66 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 53.0 | 62 | |
N2759 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 55.0 | 71 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 52.5 | 74 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 103.0 | 61 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 320.0 | 64 | |
N2586 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 164.5 | 74 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 14.0 | 85 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 22.5 | 78 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 16.0 | 85 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 64.0 | 71 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 13.5 | 58 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 19.5 | 72 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 17.0 | 74 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 48.0 | 67 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 145.0 | 82 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 142.0 | 54 |